ilShinbiobase Co., Ltd.: debt-to-equity, ROE and more

KOSDAQ, Legal name ilShinbiobase Co., Ltd.

Latest figures are the FY2025 separate summary statements.

Latest fiscal year ratios (computed here)

Debt/equity: 5.8%
Equity ratio: 94.5%
ROE: 7.4%
Op. margin: 31.3%
Rev. growth: 34.3%
Interest coverage: n/a

Condition flags

Operating profit for 5 straight years.
Total equity is above paid-in capital. Not capital-impaired.

Interest coverage and dividends (OpenDART)

Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.

Interest coverage = operating profit ÷ interest expense

No interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.

Dividends, last 3 fiscal years

Fiscal year	Cash dividend per share	Payout ratio
2025	₩10	n/a
2024	₩7	n/a
2023	₩7	n/a

Cash dividends for 3 straight years (only the 3 years OpenDART returns).

Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.

Ratios by year (computed here)

Debt-to-equity = total liabilities ÷ total equity × 100
Equity ratio = total equity ÷ total assets × 100
ROE = net income ÷ year-end total equity × 100
Operating margin = operating profit ÷ revenue × 100
Revenue growth = (this year − last year) ÷ last year × 100

Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.

Fiscal year	Debt/equity	Equity ratio	ROE	Op. margin	Rev. growth
FY2021 separate	12.7%	88.7%	11.7%	30.1%	n/a
FY2022 separate	8.6%	92.1%	7.1%	25.2%	-16.2%
FY2023 separate	6.2%	94.1%	10.9%	37.8%	-19.6%
FY2024 separate	5.8%	94.5%	6.3%	20.9%	-34.2%
FY2025 separate	5.8%	94.5%	7.4%	31.3%	34.3%

Source figures (FSC summary statements)

Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.

Fiscal year	2021	2022	2023	2024	2025
Revenue	₩24.4B	₩20.4B	₩16.4B	₩10.8B	₩14.5B
Operating profit	₩7.3B	₩5.1B	₩6.2B	₩2.3B	₩4.5B
Pre-tax income	₩7.8B	₩4.7B	₩7.8B	₩4.6B	₩5.9B
Net income	₩5.9B	₩3.8B	₩6.2B	₩3.8B	₩4.8B
Total assets	₩56.4B	₩58.5B	₩60.6B	₩63.9B	₩68.6B
Total liabilities	₩6.4B	₩4.6B	₩3.6B	₩3.5B	₩3.8B
Total equity	₩50.1B	₩53.8B	₩57.1B	₩60.4B	₩64.8B
Paid-in capital	₩4.4B	₩4.4B	₩4.4B	₩4.4B	₩4.4B
Debt/equity (source value)	12.7%	8.6%	6.2%	5.8%	5.8%

Company outline (FSC)

Market: KOSDAQ
Fiscal year end: Dec
Founded: 1994-09-27
Listed: 07/12/26
Employees: 37
Auditor: 이촌회계법인
Audit opinion: 적정의견
Corporate reg. no.: 1101111079155
Outline updated: 2026-09-24

Check the original filings

Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.

Search DART for 일신바이오

Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.